Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Simulations Plus Inc (NQ: SLP )

39.37 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Simulations Plus Inc

< Previous 1 2 3 4 Next >
Simulations Plus Outlines Paths to Win at 2023 Investor Day
From Simulations Plus, Inc.
Via Business Wire
ISoP New Board of Trustees Members Announced
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Host Investor Day on Tuesday, November 14th
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Fourth Quarter and Fiscal 2023 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Receives New FDA Grant Award
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Hosts First-of-its-Kind Virtual Summer Camp for Students and Professors
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)
From Simulations Plus, Inc.
Via Business Wire
Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases ADMET Predictor® 11
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results
From Simulations Plus, Inc.
Via Business Wire
MIDD+ 2023 Panelists Discuss How to Increase Gender Equity for Women in Science
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Sets Date for Second Quarter Fiscal Year 2023 Earnings Release and Conference Call
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Present at Sidoti March Small-Cap Conference
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
From Simulations Plus, Inc.
Via Business Wire
Lixoft Adds New Data Formatting and Reporting Modules to MonolixSuite™ in Version 2023R1
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Present at Raymond James 44th Annual Institutional Investors Conference
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus and Global Agrochemicals Leader to Collaborate on Machine Learning Models
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases Redesigned NAFLDsym® QSP Software Tool
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Executes $20 Million Accelerated Share Repurchase Agreement
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports First Quarter Fiscal 2023 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Sets Date for First Quarter Fiscal Year 2023 Earnings Release and Conference Call
From Simulations Plus, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.